A characteristic of activated glial cells is the increased expression of the peripheral benzodiazepine receptor (PBR). As glial cells are activated in a variety of cerebral disorders with associated brain injury, PBR binding is considered to be a useful marker of brain injury. The PBR ligand that has been used most frequently for brain imaging studies with positron emission tomography (PET) is [11C]-R-PK11195. In a previous study with [11C]-R- PK11195, our group had found that in comparison to control subjects, there was increased PBR binding in patients with HIV associated dementia (HAD). Although the finding showed that increased glial activity in HAD can be measured with PET, increased glial activity was not found in all expected regions. Furthermore, there were no distinguishable differences in glial activity between HIV nondemented (HIV-ND) subjects and HAD subjects. However, there was a trend showing that HIV-ND subjects had a PBR binding level that was intermediate between HAD and control subjects. A similar [11C]-R-PK11195 study by Wiley and colleagues at the University of Pittsburgh showed no significant increase in PBR binding in HIV subjects. We believe that the difficulty in achieving more conclusive results is partly due to the chemical and pharmacokinetic properties of PK11195 that make it a non-ideal PET ligand. In particular, PK11195 has high nonspecific binding, binds to plasma proteins extensively, and has low brain uptake. Thus there is a definite need for a better ligand to examine PBR binding and glial activation. Recently, a new PBR ligand known as [11C]DPA-713 has been developed in the laboratory of Dr. Michael Kassiou. As compared with [11C]-R-PK11195, which has a logP of 3.4, DPA-713 has a smaller logP of 2.4, which indicates that DPA-713 is less lipophilic than PK11195 and should have less nonspecific binding. [11C]DPA-713 also binds to PBR with higher affinity (4.7 nM), than does [11C]-R-PK11195 (9.3 nM). A baboon PET study has confirmed that [11C]DPA-713 has highly specific brain uptake. A recent study in a rat model of neuroinflammation shows that [11C]DPA-713 provides better image contrast than [11C]-R-PK11195. Attesting to the promise of this compound, at our request the NIMH has completed a toxicology package, performed by SRI International, so that DPA-713 will be translatable for use in the clinic. Here we propose to do the first-in-man study with [11C]DPA-713. Methodology will be developed to achieve reliable quantification of PBR binding with [11C]DPA-713. In addition, HIV patients will be studied to determine if [11C]DPA-713 PET can demonstrate significant differences in PBR binding between controls, HIV- ND, and HAD subjects. Since the initial application, we have invested in a GMP synthesis procedure for [11C]DPA-713, and have recently received approval for these studies from the Johns Hopkins IRB. We have begun scanning human subjects and the results thus far indicate that [11C]DPA-713 has much better brain uptake than [11C]-R-PK11195, and provides better contrast across brain regions.

Public Health Relevance

Many neurological diseases, including multiple sclerosis, AIDS dementia and Alzheimer's disease, involve an inflammatory component. Our group has been concerned with the development of tools for noninvasive imaging of inflammation in the brains of patients afflicted with these diseases. We have focused on imaging AIDS dementia with positron emission tomography (PET) and have found that by using the imaging agent [11C]-R-PK11195 we could differentiate patients with AIDS dementia from normal subjects. However, we need a more specific imaging agent that can differentiate between patients with AIDS who are not demented and those who are. A promising new agent is [11C]DPA-713, which was developed recently by our collaborators in Australia. We intend to do a first-in-man study with this new agent, and a small clinical trial in patients with AIDS. If this initial trial is successful, we will vigorously pursue [11C]DPA-713 as an imaging agent for a host of other inflammatory processes of the central nervous system.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21MH082277-03
Application #
7997226
Study Section
Special Emphasis Panel (ZRG1-MEDI-A (09))
Program Officer
Joseph, Jeymohan
Project Start
2009-01-08
Project End
2012-12-31
Budget Start
2011-01-01
Budget End
2012-12-31
Support Year
3
Fiscal Year
2011
Total Cost
$243,540
Indirect Cost
Name
Johns Hopkins University
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Wang, Yuchuan; Coughlin, Jennifer M; Ma, Shuangchao et al. (2016) Neuroimaging of translocator protein in patients with systemic lupus erythematosus: a pilot study using [11C]DPA-713 positron emission tomography. Lupus :
Coughlin, Jennifer M; Wang, Yuchuan; Munro, Cynthia A et al. (2015) Neuroinflammation and brain atrophy in former NFL players: An in vivo multimodal imaging pilot study. Neurobiol Dis 74:58-65
Coughlin, Jennifer M; Wang, Yuchuan; Ma, Shuangchao et al. (2014) Regional brain distribution of translocator protein using [(11)C]DPA-713 PET in individuals infected with HIV. J Neurovirol 20:219-32
Baba, Justin S; Endres, Christopher J; Foss, Catherine A et al. (2013) Molecular imaging of conscious, unrestrained mice with AwakeSPECT. J Nucl Med 54:969-76
Endres, Christopher J; Coughlin, Jennifer M; Gage, Kenneth L et al. (2012) Radiation dosimetry and biodistribution of the TSPO ligand 11C-DPA-713 in humans. J Nucl Med 53:330-5
Endres, Christopher J; Pomper, Martin G; James, Michelle et al. (2009) Initial evaluation of 11C-DPA-713, a novel TSPO PET ligand, in humans. J Nucl Med 50:1276-82